5.67

1.05% -0.06

Pre-market: 5.75 0.08 +1.41%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $5.67, with a volume of 2.87M. It is down -1.05% in the last 24 hours and up +0.71% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$5.73

Open:

$5.69

24h Volume:

2.87M

Relative Volume:

0.37

Market Cap:

$1.73B

Revenue:

$79.21M

Net Income/Loss:

$-143.96M

P/E Ratio:

-11.82

EPS:

-0.4796

Net Cash Flow:

$-189.60M

1W Performance:

-7.95%

1M Performance:

+0.71%

6M Performance:

+33.73%

1Y Performance:

+13.63%

1-Day Range:

$5.60

$5.87

1-Week Range:

$5.54

$6.5479

52-Week Range:

$2.745

$8.44

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (601)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	5.67	1.73B	79.21M	-143.96M	-189.60M	-0.4796
VRTX Vertex Pharmaceuticals Inc	473.09	120.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	651.91	68.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	924.60	57.84B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.75	40.13B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	268.74	35.88B	4.29B	577.22M	641.34M	4.2086

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Jul 23, 2026

Playing The Biotech Breakout With Insiders - Seeking Alpha

Jul 23, 2026

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers - marketscreener.com

Jul 23, 2026

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits

Jul 23, 2026

Jul 22, 2026